CO2019000601A2 - Derivados de oxadiazolopiridina para el uso como inhibidores de ghrelin o-aciltransferasa (goat) - Google Patents
Derivados de oxadiazolopiridina para el uso como inhibidores de ghrelin o-aciltransferasa (goat)Info
- Publication number
- CO2019000601A2 CO2019000601A2 CONC2019/0000601A CO2019000601A CO2019000601A2 CO 2019000601 A2 CO2019000601 A2 CO 2019000601A2 CO 2019000601 A CO2019000601 A CO 2019000601A CO 2019000601 A2 CO2019000601 A2 CO 2019000601A2
- Authority
- CO
- Colombia
- Prior art keywords
- ghrelin
- goat
- acyltransferase
- inhibitors
- oxadiazolopyridine derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención se refiere a los compuestos de la Fórmula general I, I en donde los grupos R1, R2 y n se definen de acuerdo con la reivindicación 1, que tienen propiedades farmacológicas valiosas, en particular, se fijan a ghrelin O-acil transferasa (GOAT) y modulan su actividad. Los compuestos son adecuados para el tratamiento y la prevención de enfermedades que se pueden ver influenciadas por este receptor, tales como enfermedades metabólicas, en particular, obesidad.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16183047 | 2016-08-05 | ||
| PCT/EP2017/069274 WO2018024653A1 (en) | 2016-08-05 | 2017-07-31 | Oxadiazolopyridine derivates for use as ghrelin o-acyl transferase (goat) inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2019000601A2 true CO2019000601A2 (es) | 2019-02-08 |
Family
ID=56609762
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2019/0000601A CO2019000601A2 (es) | 2016-08-05 | 2019-01-22 | Derivados de oxadiazolopiridina para el uso como inhibidores de ghrelin o-aciltransferasa (goat) |
Country Status (32)
| Country | Link |
|---|---|
| US (3) | US9994591B2 (es) |
| EP (1) | EP3494120B1 (es) |
| JP (1) | JP6651054B2 (es) |
| KR (1) | KR102496075B1 (es) |
| CN (1) | CN109843891B (es) |
| AR (1) | AR109296A1 (es) |
| AU (1) | AU2017307033B2 (es) |
| CA (1) | CA3033058A1 (es) |
| CL (1) | CL2019000274A1 (es) |
| CO (1) | CO2019000601A2 (es) |
| CY (1) | CY1124381T1 (es) |
| DK (1) | DK3494120T3 (es) |
| EA (1) | EA037277B1 (es) |
| ES (1) | ES2874587T3 (es) |
| HR (1) | HRP20210908T1 (es) |
| HU (1) | HUE054928T2 (es) |
| IL (1) | IL264506B (es) |
| LT (1) | LT3494120T (es) |
| MA (1) | MA45843B1 (es) |
| MX (1) | MX2019001427A (es) |
| MY (1) | MY197064A (es) |
| PE (1) | PE20190414A1 (es) |
| PH (1) | PH12019500254A1 (es) |
| PL (1) | PL3494120T3 (es) |
| PT (1) | PT3494120T (es) |
| RS (1) | RS61937B1 (es) |
| SA (1) | SA519401039B1 (es) |
| SG (1) | SG11201811804QA (es) |
| SI (1) | SI3494120T1 (es) |
| TW (1) | TWI749042B (es) |
| UA (1) | UA124267C2 (es) |
| WO (1) | WO2018024653A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019149658A1 (en) * | 2018-02-02 | 2019-08-08 | Boehringer Ingelheim International Gmbh | Pyrazole- and indazole-substituted oxadiazolopyridine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors |
| MX2020007994A (es) | 2018-02-02 | 2020-09-09 | Boehringer Ingelheim Int | Derivados de triazolopirimidina para usar como inhibidores de ghrelin o-aciltransferasa (goat). |
| EP3746450B1 (en) * | 2018-02-02 | 2022-03-16 | Boehringer Ingelheim International GmbH | Heterocyclyl-substituted oxadiazolopyridine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors |
| CR20200332A (es) * | 2018-02-02 | 2020-09-03 | Boehringer Ingelheim Int | Derivados de oxadiazolopiridina sustitidos con bencilo, (piridin-3-il)metilo o (piridin-4-il)metilo como inhibidores de ghrelin o-aciltransferasa (goat) |
| JP2023526351A (ja) | 2020-05-22 | 2023-06-21 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | アルキル７－アミノ－５－メチル－［１，２，５］オキサジアゾロ［３，４－ｂ］ピリジンカルボキシレートの製造方法 |
| EP4153600A1 (en) | 2020-05-22 | 2023-03-29 | Boehringer Ingelheim International GmbH | Continuous process for manufacturing alkyl 7-amino-5-methyl-[1,2,5]oxadiazolo[3,4-b]pyridine-carboxylate |
| CN112014340A (zh) * | 2020-09-01 | 2020-12-01 | 广西玮美生物科技有限公司 | 非人灵长类动物胃饥饿素的检测方法 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2241496B1 (es) | 2004-04-15 | 2006-12-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de piridina. |
| JP2010512366A (ja) | 2006-12-11 | 2010-04-22 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｍｃｈ拮抗活性を有する新規ピリダジン誘導体及びこれらの化合物を含む薬物 |
| EP2111414B1 (en) | 2007-02-15 | 2014-07-02 | Indiana University Research and Technology Corporation | Glucagon/glp-1 receptor co-agonists |
| DK2158214T3 (da) | 2007-06-15 | 2011-12-05 | Zealand Pharma As | Glukagonanaloger |
| BRPI0823379A2 (pt) | 2008-12-15 | 2015-07-14 | Zealand Pharma As | Análogos de glucagon |
| MX2011006314A (es) | 2008-12-15 | 2011-09-22 | Zealand Pharma As | Analogos de glucagon. |
| AU2008365555B2 (en) | 2008-12-15 | 2016-01-14 | Zealand Pharma A/S | Glucagon analogues |
| EA020596B1 (ru) | 2008-12-15 | 2014-12-30 | Зилэнд Фарма А/С | Аналоги глюкагона |
| JP6054742B2 (ja) | 2009-07-13 | 2016-12-27 | ジーランド ファーマ アクティーゼルスカブ | アシル化グルカゴン類似体 |
| AR081975A1 (es) | 2010-06-23 | 2012-10-31 | Zealand Pharma As | Analogos de glucagon |
| AU2011269430A1 (en) | 2010-06-24 | 2013-01-10 | Zealand Pharma A/S | Glucagon analogues |
| CN104144696A (zh) | 2011-12-23 | 2014-11-12 | 西兰制药公司 | 胰高血糖素类似物 |
| WO2013125732A1 (en) * | 2012-02-24 | 2013-08-29 | Takeda Pharmaceutical Company Limited | Aromatic ring compound |
| TWI608013B (zh) | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
| UA118034C2 (uk) | 2013-11-14 | 2018-11-12 | Елі Ліллі Енд Компані | Заміщений піперидилетилпіримідин як інгібітор грелін-o-ацилтрансферази |
| US20170275249A1 (en) * | 2014-09-17 | 2017-09-28 | The Regents Of The University Of California | Small lipopeptidomimetic inhibitors of ghrelin o-acyl transferase |
| AR104672A1 (es) | 2015-04-15 | 2017-08-09 | Lilly Co Eli | Inhibidores de grelina o-aciltransferasa |
| AR104673A1 (es) | 2015-04-15 | 2017-08-09 | Lilly Co Eli | Inhibidores de grelina o-aciltransferasa |
| MX2020007994A (es) | 2018-02-02 | 2020-09-09 | Boehringer Ingelheim Int | Derivados de triazolopirimidina para usar como inhibidores de ghrelin o-aciltransferasa (goat). |
| EP3746450B1 (en) | 2018-02-02 | 2022-03-16 | Boehringer Ingelheim International GmbH | Heterocyclyl-substituted oxadiazolopyridine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors |
| WO2019149658A1 (en) * | 2018-02-02 | 2019-08-08 | Boehringer Ingelheim International Gmbh | Pyrazole- and indazole-substituted oxadiazolopyridine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors |
| CR20200332A (es) | 2018-02-02 | 2020-09-03 | Boehringer Ingelheim Int | Derivados de oxadiazolopiridina sustitidos con bencilo, (piridin-3-il)metilo o (piridin-4-il)metilo como inhibidores de ghrelin o-aciltransferasa (goat) |
-
2017
- 2017-07-31 HU HUE17743064A patent/HUE054928T2/hu unknown
- 2017-07-31 PE PE2019000271A patent/PE20190414A1/es unknown
- 2017-07-31 CA CA3033058A patent/CA3033058A1/en active Pending
- 2017-07-31 EP EP17743064.2A patent/EP3494120B1/en active Active
- 2017-07-31 PL PL17743064T patent/PL3494120T3/pl unknown
- 2017-07-31 SI SI201730770T patent/SI3494120T1/sl unknown
- 2017-07-31 PT PT177430642T patent/PT3494120T/pt unknown
- 2017-07-31 US US15/664,119 patent/US9994591B2/en active Active
- 2017-07-31 LT LTEP17743064.2T patent/LT3494120T/lt unknown
- 2017-07-31 SG SG11201811804QA patent/SG11201811804QA/en unknown
- 2017-07-31 JP JP2019506164A patent/JP6651054B2/ja active Active
- 2017-07-31 AU AU2017307033A patent/AU2017307033B2/en active Active
- 2017-07-31 EA EA201990418A patent/EA037277B1/ru not_active IP Right Cessation
- 2017-07-31 CN CN201780047100.1A patent/CN109843891B/zh active Active
- 2017-07-31 DK DK17743064.2T patent/DK3494120T3/da active
- 2017-07-31 UA UAA201901840A patent/UA124267C2/uk unknown
- 2017-07-31 RS RS20210702A patent/RS61937B1/sr unknown
- 2017-07-31 KR KR1020197006448A patent/KR102496075B1/ko active IP Right Grant
- 2017-07-31 ES ES17743064T patent/ES2874587T3/es active Active
- 2017-07-31 MX MX2019001427A patent/MX2019001427A/es unknown
- 2017-07-31 MA MA45843A patent/MA45843B1/fr unknown
- 2017-07-31 WO PCT/EP2017/069274 patent/WO2018024653A1/en unknown
- 2017-07-31 MY MYPI2018002719A patent/MY197064A/en unknown
- 2017-08-04 TW TW106126319A patent/TWI749042B/zh active
- 2017-08-04 AR ARP170102213A patent/AR109296A1/es unknown
-
2018
- 2018-05-09 US US15/974,882 patent/US10308667B2/en not_active Ceased
-
2019
- 2019-01-22 CO CONC2019/0000601A patent/CO2019000601A2/es unknown
- 2019-01-28 IL IL264506A patent/IL264506B/en active IP Right Grant
- 2019-02-01 CL CL2019000274A patent/CL2019000274A1/es unknown
- 2019-02-05 SA SA519401039A patent/SA519401039B1/ar unknown
- 2019-02-06 PH PH12019500254A patent/PH12019500254A1/en unknown
-
2020
- 2020-10-14 US US17/069,940 patent/USRE49446E1/en active Active
-
2021
- 2021-06-08 HR HRP20210908TT patent/HRP20210908T1/hr unknown
- 2021-06-14 CY CY20211100525T patent/CY1124381T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2019000601A2 (es) | Derivados de oxadiazolopiridina para el uso como inhibidores de ghrelin o-aciltransferasa (goat) | |
| ECSP20050797A (es) | Derivados de triazolopirimidina para usar como inhibidores de ghrelin o-aciltransferasa (goat) | |
| ECSP20050785A (es) | Derivados de oxadiazolopiridina sustituidos con bencilo, (piridin-3-il)metilo o (piridin-4-il)metilo como inhibidores de ghrelin o-aciltransferasa (goat) | |
| CL2019000588A1 (es) | Compuestos y composiciones como inhibidores de los receptores endosomales tlr. | |
| ECSP20050791A (es) | Derivados de oxadiazolopiridina sustituidos con heterociclilo para usar como inhibidores de ghrelin o-aciltransferasa (goat) | |
| CL2018001899A1 (es) | Salicilamidas de espiroheptanos y compuestos relacionados como inhibidores de cinasa rho (rock) | |
| CR20160321A (es) | Modulares de tetrahidropiridopirazinas de gpr6 | |
| CR20180516A (es) | Compuestos de iprrolotriazina como inhibidores de tam | |
| CR20170500A (es) | Compuestos heterocíclicos como inhibidores de lsd1 | |
| SV2018005723A (es) | Derivados de tiohidantoina substituidos como antagonistas del receptor de androgenos | |
| CO2018005315A2 (es) | Moduladores de la interacción de sestrina-gator2 y sus usos | |
| NI201700029A (es) | Compuestos y composiciones como inhibidores de quinasa raf. | |
| ECSP14023238A (es) | Nuevos derivados de ácidos indaniloxidihidrobenzofuranilacéticos y sus usos como agonistas del receptor gpr40 | |
| UY37349A (es) | Composiciones y métodos para inhibir masp-3 para el tratamiento de varias enfermedades y trastornos | |
| UY36875A (es) | Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades | |
| UY35312A (es) | Ácidos indaniloxidihidrobenzofuranilacéticos como agonistas del receptor acoplado a la proteína g40 | |
| BR112016024936A2 (pt) | moduladores de gpr40 à base de pirrolidina para tratamento de doenças como diabetes | |
| CO2019002523A2 (es) | Inhibidores de dopamina–β–hidroxilasa penetrantes de la barrera hematoencefálica | |
| UY35668A (es) | Derivados de azabencimidazol como agonistas de ampk y composiciones farmacéuticas que los contienen | |
| MX2020003862A (es) | Derivados condensados de imidazol sustituidos por grupos hidroxi terciarios como inhibidores de fosfoinositido 3-cinasas gamma (pi3k-gamma). | |
| NI201801172A (es) | Nuevos compuestos para el tratamiento de enfermedades parasitarias | |
| DOP2016000211A (es) | Pirazinas moduladoras de gpr6 | |
| CL2020001461A1 (es) | Inhibidores de dopamina–b–hidroxilasa. |